664 related articles for article (PubMed ID: 35293977)
1. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
[TBL] [Abstract][Full Text] [Related]
2. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
Drucker AM; Lam M; Elsawi R; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
Br J Dermatol; 2024 Jan; 190(2):184-190. PubMed ID: 37831594
[TBL] [Abstract][Full Text] [Related]
3. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
Drucker AM; Ellis AG; Bohdanowicz M; Mashayekhi S; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Küster D; Siegels D; Schmitt J; Flohr C
JAMA Dermatol; 2020 Jun; 156(6):659-667. PubMed ID: 32320001
[TBL] [Abstract][Full Text] [Related]
4. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
[TBL] [Abstract][Full Text] [Related]
7. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL; Wong MM; Rayner DG; Guyatt GH; Díaz Martinez JP; Ceccacci R; Zhao IX; McMullen E; Srivastava A; Wang J; Wen A; Wang FC; Brignardello-Petersen R; Izcovich A; Oykhman P; Wheeler KE; Wang J; Spergel JM; Singh JA; Silverberg JI; Ong PY; O'Brien M; Martin SA; Lio PA; Lind ML; LeBovidge J; Kim E; Huynh J; Greenhawt M; Gardner DD; Frazier WT; Ellison K; Chen L; Capozza K; De Benedetto A; Boguniewicz M; Smith Begolka W; Asiniwasis RN; Schneider LC; Chu DK
J Allergy Clin Immunol; 2023 Dec; 152(6):1470-1492. PubMed ID: 37678577
[TBL] [Abstract][Full Text] [Related]
9. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
Sedeh FB; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2022 Aug; 102():adv00764. PubMed ID: 35818735
[TBL] [Abstract][Full Text] [Related]
11. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
Silverberg JI; Hong HC; Calimlim BM; Lee WJ; Teixeira HD; Collins EB; Crowell MM; Johnson SJ; Armstrong AW
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2247-2264. PubMed ID: 37658223
[TBL] [Abstract][Full Text] [Related]
14. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
[TBL] [Abstract][Full Text] [Related]
16. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis.
Nusbaum KB; Fleischer S; Fleischer AB
J Dermatolog Treat; 2022 Aug; 33(5):2534-2544. PubMed ID: 34620047
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
Zheng Y; Ding RL; Bu J
Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
